Zevra Therapeutics, Inc. (ZVRA)
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 86.6% in Zevra Therapeutics (ZVRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)
Zevra Therapeutics (ZVRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Nichol Ochsner - Vice President Neil McFarlane - President and Chief Executive Officer LaDuane Clifton - Chief Financial Officer Josh Schafer - Chief Commercial Officer Adrian Quartel - Chief Medical Officer Conference Call Participants Sumant Kulkarni - Canaccord Jason Butler - Citizens Eddie Hickman - Guggenheim Lachlan Hanbury - Brown with William Blair Operator Good afternoon and thank you for joining Zevra's First Quarter 2025 Financial Results and Corporate Update Conference Call. Today's call is being recorded, and will be available via the Investor Relations section of the company's website later today.
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.40 per share a year ago.
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Company Participants Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer and EVP, Business Development Adrian Quartel - Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Jason Butler - Citizens JMP Sumant Kulkarni - Canaccord Oren Livnat - H.C. Wainwright Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Operator Good afternoon, and thank you for joining Zevra's Therapeutics Fourth Quarter and Full Year 2024 Financial Results and Corporate Update Conference Call.
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.40 per share a year ago.
Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Nichol Ochsner - VP, IR & Corporate Communications Neil McFarlane - President & CEO LaDuane Clifton - CFO Joshua Schafer - Chief Commercial Officer & EVP, Business Development Conference Call Participants Jason Butler - JMP Securities Louise Chen - Cantor Fitzgerald Samantha Corwin - William Blair Eddie Hickman - Guggenheim Securities Sumant Kulkarni - Canaccord Genuity Oren Livnat - H.C. Wainwright Operator Good afternoon, and thank you for joining Zevra Therapeutics Third Quarter Financial Results and Corporate Update Conference Call.
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.40 per share a year ago.
Earnings Preview: Zevra Therapeutics (ZVRA) Q3 Earnings Expected to Decline
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra Stock Surges Close to 70% in 3 Months: Here's Why
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
